What made Nuvalent (NUVL) stock jump significantly at market open?

2 min read | October 28, 2022 07:43 AM PDT | By Rupam Roy

What made Nuvalent (NUVL) stock jump significantly at market open? — Image source: © Panteleev83 | Megapixl.com

Why is it rising?

Nuvalent is a biotechnology firm that specializes in chemistry and structure-based drug discovery. The clinical-stage biopharmaceutical firm claims to be precisely focusing on the targeted therapeutics to treat patients with cancer.

Meanwhile, the stock went up on Friday, after Nuvalent Inc. announced preliminary Phase 1 clinical data from the ARROS-1 trial.

ARROS-1 1/2 clinical trial of NVL-520, which is a novel brain-penetrant inhibitor, is used to treat patients suffering from advanced cell lung cancer.

It is primarily built to overcome the clinical obstacles of emergent treatment resistance, negative events relating to the central nervous system, and other related factors.

Chief Medical Officer of the firm, Christopher Turner lauded the report that showed the first look at the safety and clinical activity of the clinical trial.

Source: ©Kalkine Media®; © Canva via Canva.com

Bottom line:

The price of the NUVL stock was US$ 38.2669 at 9:41 am ET on Friday, October 28, an increase of 73.94 per cent, and its trading volume totaled 1.37 million at the same time. The stocks closed at US$ 22 in the previous session.

The company said that the data from the clinical trial would be presented in an oral plenary session in Spain.

Meanwhile, the NUVL stock soared over 92 per cent for the year after today's significant gains, and on an annual basis, it rose around 49 per cent through Friday. In the running week, it surged over 88 per cent.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.